androgen receptor result in a stimulatory effect on both the cortical and trabecular bone mass 6 in males. ERβ is of no importance for the skeleton in male mice while it modulates the ERα-7 action on bone in female mice. Previous in vitro studies suggest that the membrane G protein-8 coupled receptor (GPCR) GPR30 also might be a functional ER. Our in vivo analyses of 9 GPR30-inactivated mice revealed no function of GPR30 for estrogen-mediated effects on 10 bone mass but it is required for normal regulation of the growth plate and estrogen-mediated 11 insulin-secretion. Recent clinical evidence suggests that a threshold exists for estrogen effects 12 on bone in men: rates of bone loss and fracture risk seem to be highest in men with estradiol 13 levels below this threshold. Taken together, even though these findings do not exclude an 14 important role for testosterone in male skeletal homeostasis, it is now well-established that 15 estrogens are important regulators of bone health in men. 16
INTRODUCTION 1
Peak bone mass is higher in men than in women. After peak bone mass is reached, both men 2 and women lose bone but the bone loss is accelerated after menopause in women. Compared 3 with women, men have greater bone strength, resulting in fewer fractures. This is mainly due 4 to a larger cortical bone size in men compared with women, resulting from more bone 5 deposition at the periosteal bone surface in men during sexual maturation. Sex steroids are 6 important for the skeletal growth and maintenance of both the female and the male skeleton 7
(1). The effects of testosterone (T) can be exerted either directly through the androgen 8 receptor (AR) or indirectly via aromatization to estradiol (E2) and activation of estrogen 9 receptor (ER)α and/or β. All three of these sex steroid receptors are expressed in bone (2) (3) (4) . 10 In addition, it has recently been suggested from in vitro experiments that the membrane G 11 protein-coupled receptor (GPCR) GPR30 is also a functional ER ( Fig. 1) (5) . In this review, 12 some of our experimental animal and clinical studies exploring the role of estrogens for the 13 skeleton in males will be discussed. 14 
15

ESTROGEN RECEPTORS AND THE MALE SKELETON -LESSONS FROM 16
MOUSE STUDIES 17
Cortical bone: The larger cortical bone size in males compared with females is, at least partly, 18 due to differences in sex steroid exposure during sexual maturation. Experiments by Venken 19 et al. using male AR -/-mice have clearly demonstrated that AR activation results in cortical 20 radial bone expansion (6) . In addition, we found that male ERα -/-but not ERβ -/-mice 21 displayed reduced cortical radial bone growth during sexual maturation, demonstrating that 22
ERα but not ERβ activation is also required for a normal cortical radial bone expansion in 23 males during growth ( Fig. 2) (7) . As the cortical radial bone growth was affected during 24 sexual maturation in the male ERα -/-mice, one might speculate that the growth hormone(GH)/insulin-like growth factor I (IGF-I) axis is involved in this effect. In this context, we and 1 others have shown that a major part of serum IGF-I is liver-derived and that male ERα -/-mice 2 had a similar cortical bone phenotype as mice with liver-specific IGF-I inactivation (7) (8) (9) (10) (11) . 3 Importantly, serum IGF-I levels were reduced in the ERα -/-mice, suggesting that these 4 decreased serum IGF-I levels might mediate the reduced cortical radial bone growth seen in 5 male ERα -/-mice during sexual maturation (Fig. 2) . We, therefore, proposed that a normal 6 pubertal cortical bone expansion in males might be dependent on an early ERα-mediated 7 stimulation of the GH/IGF-I axis. 8
Trabecular bone: Similar as seen for cortical bone, both AR and ERα but not ERβ activation 9 regulate trabecular bone mass in male mice ( Fig. 1 ) (12) (13) (14) . To directly compare the effect of 10 ER activation on trabecular bone in vivo with the effect of AR activation, orchidectomized 11 wild type (WT) and ER-inactivated mice were treated with the non-aromatizable androgen 12 dihydrotestosterone (DHT), E2, or vehicle. Both ERα and AR but not ERβ activation 13 preserved the amount of trabecular bone. ERα activation resulted both in a preserved 14 thickness and number of trabeculae. In contrast, AR activation exclusively preserved the 15 number of trabeculae (13) . Furthermore, the effects of E2 could not be mediated by the AR, 16 and the effects of DHT were not reduced in ER-inactivated mice (Fig. 3) . Thus, the in vivo 17 bone-sparing effect of ERα activation is distinct from the bone-sparing effect of AR activation 18 in adult male mice. Because these two pathways are clearly distinct from each other, we 19
proposed that a combined treatment of selective ER modulators and selective AR modulators 20 might be beneficial in the treatment of male osteoporosis (13) . In contrast to the IGF-I -21 mediated effects of E2 on cortical bone during sexual maturation, the effects of E2 on 22 trabecular maintenance were not associated with the GH/IGF-I axis and seem to result from 23 direct action of E2 on bone. 24
ESTROGEN RECEPTOR β MODULATES ESTROGEN RECEPTOR α ACTIVITY 1
IN FEMALE BUT NOT MALE MICE 2
Similar as seen for males, ERα is the principal ER for the regulation of both trabecular and 3 cortical bone in female mice (15) (16) (17) (18) . However, female ERβ inactivated mice have an 4 increased cortical bone area, resulting in a loss of feminization of the cortical bone size (Fig.  5 4A) (19) . Furthermore, female ERβ -/-mice are partly protected against age-related trabecular 6 bone loss (Fig. 4B) (20) , suggesting that an ERβ antagonist might be useful in the treatment of 7 postmenopausal osteoporosis. Thus, although ERα is the principal ER for the female skeleton, 8 its activity can be modulated by ERβ. Interestingly, when we evaluated the effect of E2 in 9 female bone using global gene expression analyses, we found that the magnitude of the 10 stimulatory effect of E2 on estrogen-regulated transcripts was in general more pronounced in 11 the ERβ -/-mice than in the WT mice (21) . These data were the first to in vivo demonstrate that 12
ERβ has the capacity to reduce ERα regulated gene transcription in a global manner. This 13 inhibitory role of ERβ on ERα activity is now generally believed to be a major function of 14 ERβ in several tissues, including for the regulation of tumorigenesis. These data support a 15 "yin yang" relationship between ERα and ERβ in the female bone and possibly in other 16 tissues. It remains, however, to be determined why ERβ modulates the effect of ERα on the 17 skeleton in female but not male mice. 18 
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EVALUATION OF GPR30 AS A POTENTIAL ESTROGEN RECEPTOR IN BONE 20
In vitro studies suggest that, besides the two known nuclear ERs α and β, the membrane 21 GPR30 is also a functional ER (5, 22) . GPR30 was shown to bind E2 with high affinity in 22 vitro (5, 22) and to mediate estrogen-promoted proliferative signalling in an estrogen-23 sensitive but ER-negative breast cancer cell line (23, 24) and human endometrial cells (25) . 24
Furthermore, it was shown in vitro to mediate estrogen-dependent kinase activation as well astranscriptional responses (26, 27). However, it remained to be determined if GPR30 is an ER 1 in vivo for bone metabolism or other phenotypes. We, therefore, recently investigated the 2 possible role of GPR30 as a functional ER for the regulation of skeletal parameters using 3 GPR30 inactivated mice (28). The estrogenic responses on most of the investigated 4 parameters, including increase in bone mass (total body bone mineral density [BMD], spine 5 BMD, trabecular BMD, cortical thickness), increase in uterine weight, fat mass reduction and 6 increase in bone marrow cellularity, were similar for all of the investigated E2 doses in WT 7 and GPR30 inactivated mice, demonstrating that GPR30 is not required for normal estrogenic 8 responses on several major well-known estrogen-regulated parameters. On the other hand, 9
high dose E2 treatment reduced longitudinal bone growth, reflected by decreased femur 10 length and distal femur growth plate height, in the WT mice but not in the GPR30 inactivated 11 mice, supporting a role of GPR30 for a normal estrogenic response in the growth plate. In 12 addition, we found that GPR30 mediates E2-stimulated insulin release in vivo (29). Thus, 13 although GPR30 does not seem to be a functional ER in several major ER-responsive tissues, 14 it mediates E2-stimulated insulin release and is required for a normal estrogenic response in 15 the growth plate (28, 29). 16 
17
SERUM ESTRADIOL AND BONE GROWTH IN MEN 18
The traditional view was that estrogens and androgens were the main sex steroids influencing 19 bone maturation and maintenance in women and men, respectively. This concept has however 20 been challenged in the 1990's by the description of several 'experiments of nature'. In 1994, 21 Smith et al. described a 28-year-old man with a naturally occurring mutation in the ERα gene, 22 making him resistant to estrogen (30). This patient had undergone normal early growth and 23 developed normal male secondary sexual characteristics, but had unfused epiphyses and a 24 markedly delayed bone age of 15 years. He was tall and had experienced no pubertal growthspurt, suggesting continued linear growth into adulthood. Moreover, despite normal serum T 1 levels and elevated E2 levels, he had severe osteopenia associated with elevated markers of 2 bone remodeling. Soon thereafter, two men with estrogen deficiency, due to mutations in the 3 aromatase (CYP19) gene, were described (31, 32). These individuals had undetectable E2 4 levels and almost identical skeletal phenotypes as the estrogen-resistant man, regardless of 5 normal or elevated T levels. But, contrary to the estrogen-resistant male who had no response 6 to estrogen therapy, these aromatase-deficient men responded to estrogen treatment with a 7 significantly increased bone mass, suppression of bone resorption and growth plate closure 8 (32, 33). Since then, several new cases of aromatase deficiency have been reported, all with 9 similar baseline skeletal phenotypes as the landmark case report by Smith et al. Estrogen 10 replacement therapy, using different doses of E2, in patients with aromatase deficiency has 11 indicated that serum E2 levels above a threshold of approximately 20 pg/ml are required to 12 complete bone maturation and mineralization (32-35). 13 
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SERUM ESTRADIOL AND BONE MAINTENANCE IN MEN 15
In general, observational studies reported that serum E2 correlated better with BMD at 16 various sites than T (36-45). Moreover, prospective studies have shown that serum E2 was the 17 best predictor of both the increase in bone mass in young men (46) and the decrease of bone 18 density in elderly men (46-48). In addition, treatment of elderly men with an aromatase 19 inhibitor resulted in significant increases in bone resorption, together with decreases in bone 20 formation markers (49). This pivotal role of estrogen with respect to male skeletal metabolism 21 has since been confirmed in several other studies. Importantly, Khosla et al. suggested that, in 22 elderly men, a threshold exists for bioavailable E2 of 11pg/ml (40 pmol/l), corresponding to a 23 total E2 level of 31 pg/ml (114 pmol/l), below which the rate of bone loss at the radius and theassociation between the rate of bone loss and bioavailable E2 levels was found. Similar 1 thresholds for serum E2 were reported in elderly men by Gennari et al. The majority of estrogens in elderly men do not originate from the testes but from peripheral 5 conversion from androgens (50). Therefore, the extent of peripheral aromatase activity may 6 also influence serum E2 levels. Elderly men with a high number of repeats in the aromatase 7 gene have been reported to have higher E2 levels and decreased rates of bone loss compared 8 to men with a low number of repeats (51). In addition, this CYP19 repeat was significantly 9 associated with BMD change in elderly community-dwelling men (47). These findings 10 suggest that a genetic variation in the aromatase gene may predispose men to increased age-11 related bone loss, by modulating bone metabolism either directly or indirectly via altered 12 serum E2 levels. This notion is supported by our earlier report that CYP19 polymorphisms 13 were associated with BMD and cortical bone size in young adult Swedish men (52). Recently, 14 our extensive evaluation of 604 single nucleotide polymorphisms (SNPs) in 50 sex steroid-15 related candidate genes identified a SNP (rs 2470152) in the I.4 promoter region of the 16 aromatase gene to be clearly associated with serum E2 levels in both young adult and elderly 17 men (P=10 -14 ) (53). Importantly, subjects with the GG genotype of this CYP19 polymorphism 18 did not only have markedly elevated E2 levels but also higher lumbar spine BMD and fewer 19 prevalent fractures than subjects with the GA or AA genotypes. Interestingly, the G to A 20 transition of rs2470152 is predicted to alter a potential binding site for the transcription factor 21 cyclic AMP response element binding protein, which is thought to be important in regulating 22 aromatase expression (54). Further studies are required to test the functional significance of 23 this CYP19 promoter polymorphism on the expression of the CYP19 gene in bone and other 24 relevant tissues, and to evaluate the impact of this polymorphism on sex steroid-relateddisorders (53). In addition, a recent paper from the European Male Aging Study reported that 1 the CAG repeat length in the AR correlated to calcaneus ultrasound parameters and this was 2 associated with increased estrogen rather than decreased androgen action (55) (57) (58) (59) (60) . Previous conflicting results might be due to the fact that these 11 earlier prospective studies have been underpowered, including few incident fractures, and 12 most of them (57-59) have analyzed the baseline sex steroid levels using immunoassay-based 13 techniques, which have been shown to have a questionable specificity, especially at lower 14 concentrations. Most recently, we analyzed the predictive role of serum E2 and T levels for 15 incident fracture risk in the MrOS Sweden study, the largest population-based cohort so far 16 with sex steroid levels measured at baseline with the mass spectrometry technique (61). We 17 found that both serum E2 levels and T levels were inversely associated with fracture risk 18 when analyzed separately. However, in multivariate analyses, serum free E2 was, 19 independently of free T, a predictor of all fractures in these elderly men. Moreover, when 20 analyzing the effect of having low E2 and/or low T levels, subjects with low serum E2 levels 21
SERUM ESTRADIOL AND FRACTURES IN MEN
had an increased risk of fractures, independent of T status. In contrast, subjects with low T 22 levels but normal E2 levels were not at higher risk for fracture. In addition, the inverse 23 relationship between serum E2 levels and fracture risk was nonlinear, with a strong 24 relationship at total E2 levels below 16 pg/ml (59 pmol/l) (Fig. 5) . This observation furtherconfirms the concept of a threshold E2 level for skeletal health in men (62). The threshold E2 1 level for fracture risk described in the MrOS Sweden Study (61) is slightly lower than those 2 previously described for bone maturation, BMD and markers of bone resorption.(35, 43, 46, 3 48) This difference could be due to the fact that in the latter studies, serum E2 was analyzed 4 using immunoassay-based techniques, while it was analyzed by mass spectrometry in the 5 Swedish cohort. 
